795 related articles for article (PubMed ID: 32308352)
1. Add-on pegylated interferon augments hepatitis B surface antigen clearance
Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
[TBL] [Abstract][Full Text] [Related]
2. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
He LT; Ye XG; Zhou XY
World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
[TBL] [Abstract][Full Text] [Related]
3. Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B.
Hsu CW; Su WW; Lee CM; Peng CY; Chuang WL; Kao JH; Chu HC; Huang YH; Chien RN; Liaw YF
J Formos Med Assoc; 2018 Jul; 117(7):588-597. PubMed ID: 29456079
[TBL] [Abstract][Full Text] [Related]
4. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
[TBL] [Abstract][Full Text] [Related]
6. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
Ning Q; Han M; Sun Y; Jiang J; Tan D; Hou J; Tang H; Sheng J; Zhao M
J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
[TBL] [Abstract][Full Text] [Related]
7. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
8. Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON).
Chi H; Hansen BE; Guo S; Zhang NP; Qi X; Chen L; Guo Q; Arends P; Wang JY; Verhey E; de Knegt RJ; Xie Q; Janssen HLA
J Infect Dis; 2017 Apr; 215(7):1085-1093. PubMed ID: 28329061
[TBL] [Abstract][Full Text] [Related]
9. [HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)-ide analog: new switch study].
Hu P; Shang J; Zhang WH; Gong GZ; Li YG; Chen XY; Jiang JN; Xie Q; Dou XG; Sun YT; Li YF; Liu YX; Liu GZ; Ma DW; Chi XL; Tang H; Li XO; Xie Y; Chen XP; Jiang JJ; Zha P; Hou JL; Gao ZL; Fan HM; Ding JG; Zhang DZ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2018 Oct; 26(10):756-764. PubMed ID: 30481882
[No Abstract] [Full Text] [Related]
10. Clinical cure induced by pegylated interferon α-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort study.
Wen C; Wang Y; Tian H; Lei Y; Wang Z; Cai D; Zhou Z; Shi X
Front Cell Infect Microbiol; 2023; 13():1332232. PubMed ID: 38292859
[TBL] [Abstract][Full Text] [Related]
11. Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D.
Lampertico P; Brunetto MR; Craxì A; Gaeta GB; Rizzetto M; Rozzi A; Colombo M;
J Viral Hepat; 2019 Jan; 26(1):118-125. PubMed ID: 30187599
[TBL] [Abstract][Full Text] [Related]
12. Addition of PEG-interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic hepatitis B: Multicentre Randomized Trial (PAS Study).
Farag MS; van Campenhout MJH; Sonneveld MJ; Fung S; van Erpecum KJ; Wong DK; Verhey E; de Man R; De Knegt RJ; Brouwer JT; Baak HC; Feld JJ; Liem KS; Boonstra A; Hansen BE; Janssen HLA
J Viral Hepat; 2024 Apr; 31(4):197-207. PubMed ID: 38243144
[TBL] [Abstract][Full Text] [Related]
13. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
Li GJ; Yu YQ; Chen SL; Fan P; Shao LY; Chen JZ; Li CS; Yi B; Chen WC; Xie SY; Mao XN; Zou HH; Zhang WH
Antimicrob Agents Chemother; 2015 Jul; 59(7):4121-8. PubMed ID: 25941216
[TBL] [Abstract][Full Text] [Related]
14. Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B.
Kittner JM; Sprinzl MF; Grambihler A; Weinmann A; Schattenberg JM; Galle PR; Schuchmann M
J Clin Virol; 2012 May; 54(1):93-5. PubMed ID: 22365367
[TBL] [Abstract][Full Text] [Related]
15. Pegylated-interferon consolidation treatment versus nucleos(t)ide analogue consolidation treatment in non-cirrhotic hepatitis B patients with hepatitis B e antigen seroconversion: an open-label pilot trial.
Zhou Y; Yan R; Ru GQ; Yu LL; Yao J; Wang H
Hepatol Int; 2019 Jul; 13(4):422-430. PubMed ID: 31172416
[TBL] [Abstract][Full Text] [Related]
16. Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study).
Brouwer WP; Xie Q; Sonneveld MJ; Zhang N; Zhang Q; Tabak F; Streinu-Cercel A; Wang JY; Idilman R; Reesink HW; Diculescu M; Simon K; Voiculescu M; Akdogan M; Mazur W; Reijnders JG; Verhey E; Hansen BE; Janssen HL;
Hepatology; 2015 May; 61(5):1512-22. PubMed ID: 25348661
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B surface antigen reduction by switching from long-term nucleoside/nucleotide analogue administration to pegylated interferon.
Tamaki N; Kurosaki M; Kusakabe A; Orito E; Joko K; Kojima Y; Kimura H; Uchida Y; Hasebe C; Asahina Y; Izumi N;
J Viral Hepat; 2017 Aug; 24(8):672-678. PubMed ID: 28199034
[TBL] [Abstract][Full Text] [Related]
18. [HBeAg seroconversion achieved by sequential peginterferon alfa-2a therapy in chronic hepatitis B patients with unsatisfactory end point following entecavir treatment].
Chen XF; Chen XP; Ma XJ; Chen WL; Luo XD; Liao JY
Zhonghua Gan Zang Bing Za Zhi; 2013 Jul; 21(7):502-5. PubMed ID: 24074707
[TBL] [Abstract][Full Text] [Related]
19. Early Serum HBsAg Drop Is a Strong Predictor of HBeAg Seroconversion and HBsAg Loss to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients with Prior Nucleos(t)ide Analogue Exposure.
Chen Q; Zhang J; Huang J; Quan B; Wu X; Deng S; Han W
Med Sci Monit; 2019 Jun; 25():4665-4674. PubMed ID: 31230063
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment.
Li MH; Zhang L; Qu XJ; Lu Y; Shen G; Wu SL; Chang M; Liu RY; Hu LP; Li ZZ; Hua WH; Song SJ; Xie Y
Chin Med J (Engl); 2017 Mar; 130(5):559-565. PubMed ID: 28229987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
